Onset Expands Product Line for Cold-Chain Monitoring

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-05-2016
Volume 11
Issue 10

Onset expanded its product line for pharmaceutical cold-chain management with the launch two new products.

On Sept. 28, 2016, Onset announced that it has expanded the company’s InTemp pharmaceutical cold-chain management products with two new solutions, the InTemp CX500 Series temperature loggers and the InTempConnect cloud-based data warehousing service. Onset debuted the products at the Cold Chain GDP & Temperature Management Logistics Global Forum at the Hynes Convention Center in Boston.

Bluetooth, low-energy enabled InTemp CX500 Series loggers provide in-transit temperature monitoring, without the need to open boxes, to reduce temperature excursions and handling errors. The InTempConnect cloud-based data warehousing service enables command-center control over all logger deployments throughout the global supply chain. And like all InTemp products, the new solutions achieve 21 CFR Part 11 compliance, ensuring electronic records and electronic signatures are trustworthy and reliable.

The InTemp product family provides an alternative to manually driven pharmaceutical cold-chain monitoring solutions. Bluetooth-enabled InTemp data loggers automatically transmit mission-critical temperature data to smartphones and tablets – without the need to risk compromising the product’s environment. The InTemp mobile application allows users to track the product throughout shipment. Authorized users on the InTemp mobile application can easily view data from the loggers, check logger status, set alarms, and create and share PDF reports from their mobile devices. Three models of the loggers are available: 15-day and 90-day models for one-time use and a 365-day model for multiple uses.

Source: Onset

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Related Content